低分子受託開発製造機関の世界市場

低分子受託開発製造機関の世界市場は2030年までに2,406億米ドルに達する見込み

2024年に1,751億米ドルと推定される低分子受託開発製造機関の世界市場は、分析期間2024-2030年にCAGR 5.4%で成長し、2030年には2,406億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである低分子原薬は、CAGR 4.4%を記録し、分析期間終了時には1,503億米ドルに達すると予測されます。低分子医薬品セグメントの成長率は、分析期間中CAGR 7.3%と推定されます。

米国市場は477億米ドルと推定、中国はCAGR 8.4%で成長予測

米国の低分子受託開発製造機関市場は、2024年に477億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに478億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.3%と予測されています。欧州では、ドイツがCAGR約3.5%で成長すると予測されています。

世界の低分子CDMO市場- 主要動向と促進要因のまとめ

低分子CDMOが世界の医薬品サプライチェーンで重要な柱となった理由とは？

低分子受託開発製造機関（CDMO）は、医薬品バリューチェーンに不可欠な存在となり、原薬（API）および製剤（製剤）開発のためのエンドツーエンドのサービスを提供しています。製薬企業が業務を合理化し、市場投入までの時間を短縮し、コストと生産能力の圧力に対応するにつれ、複雑な低分子プロジェクトを専門のCDMOに委託するケースが増えています。このようなパートナーは、前臨床段階の研究開発から商業生産へとスケールアップするために極めて重要な要素である、プロセス化学に関する深い専門知識、世界の規制への理解、高度なインフラをもたらします。

低分子は、特に腫瘍学、心臓病学、中枢神経系疾患、感染症などの領域で、現在も市販されている医薬品の大部分を占めています。比較的安定した製剤、確立された規制経路、経口バイオアベイラビリティにより、生物学的製剤ブームの中でさえ、低分子は支配的な治療手段となっています。その結果、大手製薬会社だけでなく、医薬品候補を上市するためにスケーラブルでGMPに準拠したインフラを必要とする中堅企業やバイオベンチャー企業にとっても、低分子医薬品の強力な能力を持つCDMOは依然として高い人気を誇っています。

テクノロジーと規制の複雑さはCDMOのサービスモデルをどのように形成しているか？

最新のCDMOが提供するサービスの範囲は、基本的な受託製造から包括的で統合された提供へと進化しています。これには、プロセス開発、分析法バリデーション、固体化学、規制当局への申請サポート、製剤設計、包装ソリューションなどが含まれます。先進的なCDMOは、サイクルタイム、環境フットプリント、バッチあたりのコストを削減するために、連続製造、グリーンケミストリー、自動化技術に投資しています。

同時に、規制環境も複雑化しています。FDA、EMA、PMDAのような機関は、より深いプロセスの透明性、データの完全性、Quality-by-Design（QbD）アプローチを要求しています。CDMOは、堅牢なデジタル文書化システム、リアルタイムのバッチ分析、施設全体の厳格な品質システムを通じて、これらの期待に応えなければならないです。世界の規制調和が進むにつれ、多国籍企業の顧客は、国境を越えたコンプライアンスに関する専門知識と複数施設の規制認定を有するCDMOを求めており、高業績ベンダー間の統合傾向に拍車をかけています。

低分子CDMOの需要が最も急増しているのはどこですか？

低分子CDMOに対する需要が最も急増しているのは新興バイオファーマであり、現在、世界の初期段階の医薬品開発活動の大半を占めています。これらの企業は、社内に製造能力がないため、製造委託に大きく依存しています。がん領域と希少疾患領域は、その多くが低分子を主成分としており、特に第I相および第II相臨床試験で大きなプロジェクト量に貢献しています。ブロックバスター医薬品の特許の崖が近づいているため、大手製薬会社はジェネリック医薬品や、配合剤や合剤を含むライフサイクルの延長業務もアウトソーシングしています。

地域別では、北米が依然として最大の市場であり、規制の厳しさと高品質の基準がプレミアムCDMOパートナーの需要を高めている欧州が僅差で続いています。しかし、アジア太平洋地域は、特にインドと中国において、競争力のあるコスト構造、GMP遵守の拡大、人材プールの増加を背景に、重要な製造拠点として台頭してきています。また、米国と欧州ではオンショアリングの取り組みが顕著に増加しており、CDMOは地政学的リスクを軽減し、サプライチェーンの継続性を確保するため、現地生産能力を拡大する必要に迫られています。

低分子CDMO市場の成長はいくつかの要因に牽引されている...

医薬品開発のライフサイクル全体にわたって、スケーラブルで高品質なアウトソーシング・ソリューションに対する需要が持続しているため、市場は拡大しています。特に慢性疾患や新興疾患を対象とする低分子医薬品が世界のパイプラインで優位を占めており、根強い需要が確実なものとなっています。新興バイオファーマによる研究開発投資の増加は、限られた社内製造資源と相まって、CDMO依存に拍車をかけています。連続製造、高力価化合物の取り扱い、デジタルプロセス分析における技術的進歩は、CDMOの価値提案を高めています。さらに、規制の複雑化、GMP遵守のプレッシャー、サプライチェーンの世界化により、製薬企業は長期的かつ戦略的なアウトソーシングパートナーシップを結ぶようになっています。アジア太平洋地域の成長は、主要CDMOの生産能力拡大やM&A活動と相まって、臨床・商業段階における市場の勢いをさらに加速させています。

セグメント

製品タイプ（低分子原薬、低分子医薬品）、ステージ（前臨床ステージ、臨床ステージ、商業ステージ）、治療領域（がん治療領域、心血管疾患治療領域、呼吸器疾患治療領域、神経治療領域、代謝疾患治療領域、その他治療領域）、エンドユーザー（製薬・バイオテクノロジー企業エンドユーザー、研究機関・アカデミックエンドユーザー）

調査対象企業の例

• Ajinomoto Bio-Pharma Services
• Aenova Group
• Alcami Corporation
• Amgen Inc.
• Aurigene Pharmaceutical Services Ltd.
• Bellen Chemistry
• Boehringer Ingelheim
• Cambrex Corporation
• Catalent, Inc.
• CordenPharma International
• CoreRx, Inc.
• Delpharm
• Eurofins Scientific
• Hovione
• Labcorp Drug Development
• Lonza Group Ltd.
• Pace Analytical Services, LLC
• Piramal Pharma Solutions
• WuXi AppTec Co., Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Small Molecules Contract Development and Manufacturing Organization Market to Reach US$240.6 Billion by 2030

The global market for Small Molecules Contract Development and Manufacturing Organization estimated at US$175.1 Billion in the year 2024, is expected to reach US$240.6 Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Small Molecule API, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$150.3 Billion by the end of the analysis period. Growth in the Small Molecule Drug Products segment is estimated at 7.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$47.7 Billion While China is Forecast to Grow at 8.4% CAGR

The Small Molecules Contract Development and Manufacturing Organization market in the U.S. is estimated at US$47.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$47.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Small Molecules CDMO Market - Key Trends & Drivers Summarized

Why Are Small Molecule CDMOs Now Critical Pillars in Global Pharma Supply Chains?

Small Molecule Contract Development and Manufacturing Organizations (CDMOs) have become integral to the pharmaceutical value chain, offering end-to-end services for drug substance (API) and drug product (formulation) development. As pharmaceutical companies streamline operations, reduce time-to-market, and respond to cost and capacity pressures, they are increasingly outsourcing complex small molecule projects to specialized CDMOs. These partners bring deep process chemistry expertise, global regulatory understanding, and advanced infrastructure-factors crucial for scaling from preclinical R&D to commercial manufacturing.

Small molecules still account for the vast majority of drugs on the market, particularly in areas like oncology, cardiology, CNS disorders, and infectious diseases. Their relatively stable formulations, well-established regulatory pathways, and oral bioavailability make them the dominant therapeutic modality even amid the biologics boom. Consequently, CDMOs with robust small molecule capabilities remain highly sought after-not only by large pharmaceutical companies but also by mid-sized firms and biotech startups needing scalable, GMP-compliant infrastructure to bring drug candidates to market.

How Are Technology and Regulatory Complexity Shaping CDMO Service Models?

The scope of services provided by modern CDMOs has evolved from basic contract manufacturing to comprehensive, integrated offerings. These include process development, analytical method validation, solid-state chemistry, regulatory submission support, formulation design, and packaging solutions. Advanced CDMOs are investing in continuous manufacturing, green chemistry, and automation technologies to reduce cycle times, environmental footprint, and cost per batch-an advantage especially for high-volume or niche indication drugs.

Simultaneously, the regulatory environment is growing more intricate. Agencies like the FDA, EMA, and PMDA are requiring deeper process transparency, data integrity, and quality-by-design (QbD) approaches. CDMOs must meet these expectations through robust digital documentation systems, real-time batch analytics, and stringent quality systems across facilities. As global regulatory harmonization gains traction, multinational clients are seeking CDMOs with cross-border compliance expertise and multi-site regulatory accreditations-spurring a consolidation trend among high-performing vendors.

Where Is Demand for Small Molecule CDMOs Surging the Most?

The fastest-growing demand for small molecule CDMOs is coming from emerging biopharma, which now accounts for the majority of early-stage drug development activity worldwide. These companies rely heavily on outsourced manufacturing due to lack of in-house capabilities. Oncology and rare disease segments-many of which are dominated by small molecules-are contributing significant project volume, especially for Phase I and II clinical trials. As patent cliffs approach for blockbuster drugs, large pharma companies are also outsourcing generics and lifecycle extension work, including reformulations and fixed-dose combinations.

Regionally, North America remains the largest market, followed closely by Europe, where regulatory stringency and high-quality standards elevate demand for premium CDMO partners. However, Asia-Pacific is emerging as a key manufacturing hub, particularly in India and China, driven by competitive cost structures, expanding GMP compliance, and growing talent pools. There is also a notable rise in onshoring initiatives in the US and Europe, prompting CDMOs to expand local capacity to mitigate geopolitical risks and ensure supply chain continuity.

The Growth in the Small Molecules CDMO Market Is Driven by Several Factors…

The market is expanding due to sustained demand for scalable, high-quality outsourcing solutions across the drug development lifecycle. The dominance of small molecule drugs in global pipelines, particularly for chronic and emerging diseases, ensures strong underlying demand. Rising R&D investments by emerging biopharma, coupled with limited internal manufacturing resources, are fueling CDMO dependency. Technological advancements in continuous manufacturing, high-potency compound handling, and digital process analytics are increasing the value proposition of CDMOs. Additionally, rising regulatory complexity, GMP compliance pressures, and supply chain globalization are prompting pharmaceutical companies to form long-term, strategic outsourcing partnerships. Regional growth in Asia-Pacific, combined with capacity expansions and M&A activity among leading CDMOs, is further amplifying market momentum across clinical and commercial phases.

SCOPE OF STUDY:

The report analyzes the Small Molecules Contract Development and Manufacturing Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Small Molecule API, Small Molecule Drug Products); Stage (Preclinical Stage, Clinical Stage, Commercial Stage); Therapeutic Area (Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area, Neurology Therapeutic Area, Metabolic Disorders Therapeutic Area, Other Therapeutic Areas); End-Use (Pharma & Biotech Companies End-Use, Research Institutes & Academics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Ajinomoto Bio-Pharma Services
• Aenova Group
• Alcami Corporation
• Amgen Inc.
• Aurigene Pharmaceutical Services Ltd.
• Bellen Chemistry
• Boehringer Ingelheim
• Cambrex Corporation
• Catalent, Inc.
• CordenPharma International
• CoreRx, Inc.
• Delpharm
• Eurofins Scientific
• Hovione
• Labcorp Drug Development
• Lonza Group Ltd.
• Pace Analytical Services, LLC
• Piramal Pharma Solutions
• WuXi AppTec Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Small Molecules Contract Development and Manufacturing Organization - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Resurgence of Small Molecule Drug Pipelines Propels Growth of CDMO Partnerships
  • Rising Complexity of API Synthesis Strengthens Business Case for Outsourced Small Molecule Manufacturing
  • Increased Demand for Accelerated Clinical Development Timelines Spurs CDMO Adoption
  • Expansion of Oncology and CNS Drug Development Pipelines Generates Demand for Specialized CDMO Capabilities
  • Outsourcing by Emerging Biopharma Expands Addressable Market for CDMOs Focused on Small Molecules
  • Regulatory Pressure to Ensure GMP Compliance Drives Demand for Experienced CDMO Partners
  • High Cost of In-House Manufacturing Infrastructure Boosts Reliance on End-to-End CDMO Solutions
  • Trend Toward Continuous Manufacturing in Small Molecules Creates Opportunities for Process-Capable CDMOs
  • Shift Toward Niche and Orphan Drug Development Spurs Need for Flexible, Small-Scale CDMO Operations
  • Growing Adoption of Green Chemistry in Pharma Manufacturing Drives Innovation Across CDMOs
  • Rapid Globalization of Clinical Trials Expands Demand for CDMOs with Multiregional Regulatory Expertise
  • Supply Chain Disruptions and Risk Mitigation Strategies Accelerate Dual Sourcing Through CDMOs
  • Digitalization and Data Analytics in Drug Development Strengthen Competitive Edge for Smart CDMOs
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Small Molecules Contract Development and Manufacturing Organization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Small Molecule API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Small Molecule API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecule Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Small Molecule Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Small Molecule Drug Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Metabolic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Metabolic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Metabolic Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Cardiovascular Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Cardiovascular Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Respiratory Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Respiratory Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Research Institutes & Academics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Research Institutes & Academics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Research Institutes & Academics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Preclinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Preclinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Preclinical Stage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Clinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Clinical Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Clinical Stage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Commercial Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Commercial Stage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Commercial Stage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• JAPAN
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• CHINA
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 80: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• EUROPE
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• FRANCE
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 107: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• GERMANY
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 143: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• INDIA
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 218: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 319: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 334: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 346: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 370: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030
• AFRICA
  • Small Molecules Contract Development and Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by Product Type - Small Molecule API and Small Molecule Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 394: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Product Type - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Products for the Years 2014, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Therapeutic Area - Percentage Breakdown of Value Sales for Metabolic Disorders Therapeutic Area, Other Therapeutic Areas, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Respiratory Disorders Therapeutic Area and Neurology Therapeutic Area for the Years 2014, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by End-Use - Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Research Institutes & Academics End-Use for the Years 2014, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Small Molecules Contract Development and Manufacturing Organization by Stage - Preclinical Stage, Clinical Stage and Commercial Stage Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Small Molecules Contract Development and Manufacturing Organization by Stage - Percentage Breakdown of Value Sales for Preclinical Stage, Clinical Stage and Commercial Stage for the Years 2014, 2025 & 2030

IV. COMPETITION